Fibronostics at AASLD Liver Meeting 2025
Fibronostics is thrilled to announce its participation in the AASLD Liver Meeting 2025, the world’s leading conference dedicated to advancing […]
Resources
Fibronostics Acquires Stone Clinical Labs for MASH/MASLD Diagnostic Innovation
We’re excited to announce that Fibronostics has completed the acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced
Fibronostics Joins Experts in Liver Health at THASL 2025 Bangkok
On June 11-13, Fibronostics had the privilege of participating in the THASL 2025 Annual Conference, hosted by the Thai Association
LIVERFASt (L-FAST) Identifies Advanced (F3F4, AF) and Clinically Significant Fibrosis (F2-F4, CSF) in MASLD Patients
In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4
Fibronostics to Exhibit at THASL 2025 Annual Conference in Bangkok
Fibronostics is pleased to announce its participation in the THASL 2025 Annual Conference, hosted by the Thai Association for the Study of the
Fibronostics Achieves SOC 2 Compliance
Fibronostics is now officially SOC 2 Type II compliant! This compliance reflects our deep commitment to keeping your data and
Fibronostics is ISO27001:2022 Certified Yet Again in 2025
We did it again! Fibronostics is proud to announce that we have successfully renewed our ISO 27001:2022 certification for
We have achieved ISO27001:2022 certification
Fibronostics is proud to announce that we have achieved ISO27001:2022 certification, another significant milestone in our company’s journey towards excellence
LIVERSTAT is now a Notified Medical Device
We are thrilled to announce that LIVERSTAT, our software as medical device (SaMD) has been officially listed as a Class
Fibronostics Team at SHC 2024
Our team had an incredible experience during the Singapore Hepatology Conference 2024 held at Grand Hyatt Hotel, Singapore .We’ve had